Table 3: Effect of andrographolide on liver biomarkers in hyperlipidemic rats.

Albumin (G/L)TB (umol/L)AP (IU/L)ALT (IU/L)AST (IU/L)

Group 114 ± 0.37*3 ± 0.0060.67 ± 2.82*58 ± 0.52*214.6 ± 8.01*
Group 211.67 ± 0.212.5 ± 0.2284.17 ± 0.9565.17 ± 0.87184 ± 3.98
Group 313 ± 0.00*2.5 ± 0.2268.83 ± 0.95*65.83 ± 2.54216.8 ± 3.25*
Group 413.33 ± 0.21*2.5 ± 0.2263.17 ± 1.81*59.17 ± 0.87*238.3 ± 12.1*
Group 512.67 ± 0.21*2 ± 0.0062.67 ± 1.93*48.33 ± 1.8*236.5 ± 2.43*

Albumin (4,25) = 11.2, < 0.001, (TB) Total bilirubin; (4,25) = 4.2, < 0.05, (AP) Alkaline phosphatase; (4,25) = 27.4, < 0.001, (ALT) Alanine aminotransferase; (4,25) = 21.7, < 0.001, (AST) Aspartate aminotransferase; (4,25) = 9.9, < 0.001.
Group (1) vehicle; Group (2) vehicle and P. gingivalis; Group (3) simvastatin (100 mg/kg); Group (4) andrographolide 20 mg/kg; Group (5) andrographolide 10 mg/kg. Statistical Analysis of the data was carried out using a one-way analysis of variance (ANOVA) and Dennett’s post hoc test for average comparison on SPSS 18.0. Mean values SEM ( = 6) were used. Significance was defined as * < 0.05 compared to G2. Values without an asterisk do not have significant difference compared to G2.